Key Insights

Highlights

Treatment Research

6 treatments under study, led by Tegafur Gimeracil And Oteracil Potassium Capsules

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total

P 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials

NCT07643623Phase 2RecruitingPrimary

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Showing all 1 trials

Research Network

Common Treatments

Tegafur Gimeracil And Oteracil Potassium Capsules1
Ipilimumab N01 Placebo1
Ipilimumab N011
Sintilimab Placebo1
Sintilimab1

Active Sponsors

Innovent Biopharmaceutical Technology Hangzhou Co Ltd1